These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27665855)

  • 1. Evaluation of plasma PCSK9 concentrations, transcript of LDL receptor, as well as the total number of monocyte LDL receptors in acute coronary syndrome patients.
    Burchardt P; Rzeźniczak J; Dudziak J; Dżumak A; Marchlewski T; Ganowicz-Kaatz T; Popiak M; Słomczyński M; Jezierski M; Laskowski W; Łuczak T; Plewa R
    Cardiol J; 2016; 23(6):604-609. PubMed ID: 27665855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study.
    Cariou B; Guérin P; Le May C; Letocart V; Arnaud L; Guyomarch B; Pichelin M; Probst V
    Diabetes Metab; 2017 Dec; 43(6):529-535. PubMed ID: 28865748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children.
    Girona J; Rodríguez-Borjabad C; Ibarretxe D; Heras M; Amigo N; Feliu A; Masana L; Plana N;
    J Clin Lipidol; 2018; 12(1):211-218. PubMed ID: 29102496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations Between Soluble LDLR and Lipoproteins in a White Cohort and the Effect of PCSK9 Loss-of-Function.
    Mayne J; Ooi TC; Tepliakova L; Seebun D; Walker K; Mohottalage D; Ning Z; Abujrad H; Mbikay M; Wassef H; Chrétien M; Figeys D
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3486-3495. PubMed ID: 29982529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of PCSK9 levels in patients with acute coronary syndromes.
    Gencer B; Montecucco F; Nanchen D; Carbone F; Klingenberg R; Vuilleumier N; Aghlmandi S; Heg D; Räber L; Auer R; Jüni P; Windecker S; Lüscher TF; Matter CM; Rodondi N; Mach F
    Eur Heart J; 2016 Feb; 37(6):546-53. PubMed ID: 26655339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease.
    Hu D; Yang Y; Peng DQ
    Int J Cardiol; 2017 Jan; 227():61-65. PubMed ID: 27846466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of subclinical hypothyroidism on serum lipid profile, PCSK9 levels and CD36 expression on monocytes.
    Fazaeli M; Khoshdel A; Shafiepour M; Rohban M
    Diabetes Metab Syndr; 2019; 13(1):312-316. PubMed ID: 30641718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype.
    Drouin-Chartier JP; Tremblay AJ; Hogue JC; Ooi TC; Lamarche B; Couture P
    Metabolism; 2015 Nov; 64(11):1541-7. PubMed ID: 26371983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between protein convertase subtilisin kexin type-9 levels and extent of coronary artery disease in patients with non-ST-elevation myocardial infarction.
    Dalgic Y; Abaci O; Kocas C; Cetinkal G; Dalgic SN; Buyuk A; Ser OS; Batit S; Arat A; Gurmen AT
    Coron Artery Dis; 2020 Jan; 31(1):81-86. PubMed ID: 31206403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis.
    Liberale L; Carbone F; Bertolotto M; Bonaventura A; Vecchié A; Mach F; Burger F; Pende A; Spinella G; Pane B; Camici GG; Palombo D; Dallegri F; Montecucco F
    Int J Cardiol; 2018 Jul; 263():138-141. PubMed ID: 29754909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome.
    Buchner S; Debl K; Barlage S; Griese D; Fredersdorf S; Jeron A; Lubnow M; Müller T; Muders F; Holmer S; Riegger GA; Luchner A
    Clin Chem Lab Med; 2010 Jun; 48(6):875-81. PubMed ID: 20441480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K; Park BS; Kim YW; Vaziri ND
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat.
    Zhang Y; Liu J; Li S; Xu RX; Sun J; Tang Y; Li JJ
    BMC Cardiovasc Disord; 2014 Dec; 14():192. PubMed ID: 25519174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
    J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome.
    Cyr Y; Lamantia V; Bissonnette S; Burnette M; Besse-Patin A; Demers A; Wabitsch M; Chrétien M; Mayer G; Estall JL; Saleh M; Faraj M
    Physiol Rep; 2021 Feb; 9(3):e14721. PubMed ID: 33527668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
    Tavori H; Rashid S; Fazio S
    Atherosclerosis; 2015 Feb; 238(2):264-70. PubMed ID: 25544176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.